BACKGROUND AND PURPOSE: Uncertainty is an aversive experience and plays an important role in the lives of men undergoing active surveillance (AS; earlier referred to as watchful waiting) for early-stage prostate cancer. Yet reliable and valid measures of uncertainty have not been fully tested in this population. This secondary analysis therefore tested the reliability of the Mishel Uncertainty in Illness Scale Community Form (MUIS-C; M.H. Mishel, 1997b) for use with men undergoing AS for prostate cancer. METHODS: Item-Total correlations were conducted on the 23 items of the MUIS-C with four samples of men undergoing AS. RESULTS: Cronbach's alpha for the full MUIS-C was .908; 22 of 23 items showed significant positive correlations with the total score. Removing the item without a significant correlation from the reliability analysis increased Cronbach's alpha to .913. CONCLUSIONS: The Mishel Uncertainty in Illness Scale-Community Form for Active Surveillance is a reliable and valid tool for measuring uncertainty with men undergoing AS for prostate cancer.
BACKGROUND AND PURPOSE: Uncertainty is an aversive experience and plays an important role in the lives of men undergoing active surveillance (AS; earlier referred to as watchful waiting) for early-stage prostate cancer. Yet reliable and valid measures of uncertainty have not been fully tested in this population. This secondary analysis therefore tested the reliability of the Mishel Uncertainty in Illness Scale Community Form (MUIS-C; M.H. Mishel, 1997b) for use with men undergoing AS for prostate cancer. METHODS: Item-Total correlations were conducted on the 23 items of the MUIS-C with four samples of men undergoing AS. RESULTS: Cronbach's alpha for the full MUIS-C was .908; 22 of 23 items showed significant positive correlations with the total score. Removing the item without a significant correlation from the reliability analysis increased Cronbach's alpha to .913. CONCLUSIONS: The Mishel Uncertainty in Illness Scale-Community Form for Active Surveillance is a reliable and valid tool for measuring uncertainty with men undergoing AS for prostate cancer.
Authors: Merle H Mishel; Barbara B Germino; Karen M Gil; Michael Belyea; Iris Carlton Laney; Janet Stewart; Laura Porter; Margaret Clayton Journal: Psychooncology Date: 2005-11 Impact factor: 3.894
Authors: Christopher Warlick; Bruce J Trock; Patricia Landis; Jonathan I Epstein; H Ballentine Carter Journal: J Natl Cancer Inst Date: 2006-03-01 Impact factor: 13.506
Authors: Donald E Bailey; Lawrence Landerman; Julie Barroso; Patricia Bixby; Merle H Mishel; Andrew J Muir; Lisa Strickland; Elizabeth Clipp Journal: Psychosomatics Date: 2009 Mar-Apr Impact factor: 2.386
Authors: Alok Vij; Marc A Kowalkowski; Tae Hart; Heather Honoré Goltz; David J Hoffman; Sara J Knight; Peter R Caroll; David M Latini Journal: J Cancer Educ Date: 2013-12 Impact factor: 2.037
Authors: Patricia A Parker; John W Davis; David M Latini; George Baum; Xuemei Wang; John F Ward; Deborah Kuban; Steven J Frank; Andrew K Lee; Christopher J Logothetis; Jeri Kim Journal: BJU Int Date: 2015-04-21 Impact factor: 5.588
Authors: Kim Donachie; Erik Cornel; Thomas Pelgrim; Leslie Michielsen; Bart Langenveld; Marian Adriaansen; Esther Bakker; Lilian Lechner Journal: Support Care Cancer Date: 2022-01-26 Impact factor: 3.359
Authors: Lisa Guccione; Krista Fisher; Linda Mileshkin; Richard Tothill; David Bowtell; Stephen Quinn; Anna DeFazio; Chris S Karapetis; Nicholas Wilcken; Madhu Singh; Christopher Steer; Bo Gao; Mark Warren; Ian M Collins; Narayan Karanth; Cindy Bryant; Penelope Schofield Journal: Support Care Cancer Date: 2022-07-09 Impact factor: 3.359